Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide

Molecular Cancer Therapeutics

Volumn 3, Issue 10, 2004, Pages 1221-1227

  Jiang, Xiuxian ^a   Zhao, Baoguang ^c   Britton, Robert ^a   Lim, Lynette Y ^a   Leong, Dan ^b   Sanghera, Jasbinder S ^b   Zhou, Bin Bing S ^d,e   Piers, Edward ^a   Andersen, Raymond J ^a   Roberge, Michel ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Kinetek Pharmaceuticals Inc   (Canada)

^c Department of Structural Biology ^*  (Canada)

^d GLAXOSMITHKLINE   (United States)

^e Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 METHYLGRANULATIMIDE; 17 METHYLGRANULATIMIDE; 7 HYDROXYSTAUROSPORINE; 9 HYDROXYISOGRANULATIMIDE; ADENOSINE TRIPHOSPHATE; AMIDE; ANTINEOPLASTIC AGENT; CARBONYL DERIVATIVE; CHECKPOINT KINASE 1; CYSTEINE; GLUTAMIC ACID; GLYCINE; GLYCOGEN SYNTHASE KINASE 3BETA; GRANULATIMIDE; HYDROGEN; IMIDAZOLE; IMIDE; INDOLE DERIVATIVE; ISOGRANULATIMIDE A; ISOGRANULATIMIDE B; ISOGRANULATIMIDE C; ISOGRANULATIMIDE DERIVATIVE; MALEIMIDE DERIVATIVE; NITROGEN; OXYGEN; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; BISINDOLYLMALEIMIDE; GLUTAMINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; IMIDAZOLE DERIVATIVE; ISOGRANULATIMIDE; PROTEIN KINASE; PROTEIN KINASE C;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA DAMAGE; DRUG DETERMINATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DOMAIN; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME ACTIVE SITE; METABOLISM; PHENOTYPE; PHYSIOLOGY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; TIME; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYSTEINE; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; GLUTAMINE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMIDAZOLES; INDOLES; INHIBITORY CONCENTRATION 50; MALEIMIDES; MODELS, CHEMICAL; MODELS, MOLECULAR; NITROGEN; PHENOTYPE; PROTEIN BINDING; PROTEIN KINASE C; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS;

EID: 7444245571     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 2 DNA damage checkpoint and their potential for cancer therapy. Prog Cell Cycle Res 2003;5:423-30.
2. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992;89:7491-5.
3. Walworth NC. Cell cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol 2000;12:697-704.
4. Hartwell L, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-8.
5. O'Connor PM. Cell cycle checkpoints: targets for anticancer therapy. Anticancer Drugs 1996;7:135-41.
6. Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 2001;93:1434-6.
7. Sampath D, Plunkett W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr Opin Oncol 2001;13:484-90.
8. Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 1999;104:1645-53.
9. Flatt P, Pietenpol J. Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Drug Metab Rev 2000;32:283-305.
10. Goodarzi AA, Block WD, Lees-Miller SP. The role of ATM and ATR in DNA damage-induced cell cycle control. Frog Cell Cycle Res 2003;5: 393-411.
11. Zhou BB, Sausville EA. Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 2003;5:413-21.
12. 2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res 1998;58:5701-6.
13. Roberge M, Cinel B, Anderson HJ, et al. Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin and paclitaxel in natural extracts. Cancer Res 2000;60:5052-8.
14. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
15. 2 arrest through a cdk2-dependent pathway that involves inactivation of the Wee 1hu kinase. J Biol Chem 1998;273:33455-64.
16. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7.
17. Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5.
18. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60:2108-12.
19. Jackson JR, Gilmartin A, Imburgia C, et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000;60:566-72.
20. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 (7-hydroxystaurosporine) in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-33.
21. 2 checkpoint inhibitor. Syntheses of didemnimide C, isodidemnimide A, neodidemnimide A, 17-methylgranulatimide, and isogranulatimides A-C. J Org Chem 2000; 65:530-5.
22. Anderson HJ, deJong G, Vincent I, Roberge M. Flow cytometry of mitotic cells. Exp Cell Res 1998;238:498-502.
23. Robbins DJ, Zhen E, Owaki H, et al. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J Biol Chem 1993;268:5097-106.
24. Zheng CF, Guan KL. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J Biol Chem 1993;268:11435-9.
25. Charlton LA, Sanghera JS, Clark-Lewis I, Pelech SL. Structure-function analysis of casein kinase 2 with synthetic peptides and anti-peptide antibodies. J Biol Chem 1992;267:8840-5.
26. Persad S, Attwell S, Gray V, et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 34. J Biol Chem 2001;276: 27462-9.
27. Morrison DL, Sanghera JS, Stewart J, et al. Phosphorylation and activation of smooth muscle myosin light chain kinase by MAP kinase and cyclin-dependent kinase-1. Biochem Cell Biol 1996;74:549-57.
28. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. pp60c-src activation in human colon carcinoma. J Clin Invest 1989;83:2025-33.
29. Paz K, Liu YF, Shorer H, et al. Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem 1999;274:28816-22.
30. Bazzi MD, Nelsestuen GL. Role of substrate in determining the phospholipid specificity of protein kinase C activation. Biochemistry 1987;26:5002-8.
31. Palaty CK, Clark-Lewis I, Leung D, Pelech SL. Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase. Biochem Cell Biol 1997;75:153-62.
32. Block WD, Merkle D, Meek K, Lees-Miller SP. Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine. Nucleic Acids Res 2004;32:1967-72.
33. Watts JD, Wilson GM, Ettenhadieh E, et al. Purification and initial characterization of the lymphocyte-specific protein-tyrosyl kinase p56Ick from a baculovirus expression system. J Biol Chem 1992;267:901-7.
34. Thomas GM, Frame S, Goedert M, et al. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalyzed phosphorylation of axin and β-catenin. FEBS Lett 1999;458:247-51.
35. Machu TK, Olsen RW, Browning MD. Ethanol has no effect on cAMP-dependent protein kinase-, protein kinase C, or Ca(2+)-calmodulin-dependent protein kinase II-stimulated phosphorylation of highly purified substrates in vitro. Alcohol Clin Exp Res 1991;15:1040-4.
36. Tuazon PT, Chinwah M, Traugh JA. Autophosphorylation and protein kinase activity of p21-activated protein kinase -PAK are differentially affected by magnesium and manganese. Biochemistry 1998;37:17024-9.
37. Zhao B, Bower MJ, McDevitt PJ, et al. Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002;277:46609-15.
38. Dang LH, Bettegowda C, Agrawal N, et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004;3:326-37.
39. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888-92.
40. Aimes RT, Hemmer W, Taylor ST. Serine-53 at the tip of the glycine-rich loop of cAMP-dependent protein kinase: role in catalysis, P-site specificity, and interaction with inhibitors. Biochemistry 2000;39:8325-32.